Risen (Suzhou) Pharma Tech Co., Ltd.

Quick facts

Phase 3 pipeline

• JS105 · Diabetes
  JS105 is a small molecule that targets the SGLT2 receptor.

Phase 1 pipeline

• RP903

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Risen (Suzhou) Pharma Tech Co., Ltd. portfolio CI brief
• Risen (Suzhou) Pharma Tech Co., Ltd. pipeline updates RSS